Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q1 EPS of ($0.68), $0.06 worse than the analyst estimate of ($0.62). Revenue for the quarter came in at $50 thousand versus the consensus estimate of $9.73 thousand.

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.